Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

References

• Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. PNAS. 2012;109:2802–7. doi:10.1073/pnas.1108781108. PMID:21908711.
   PubMed Web of Science ®Google Scholar
• Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, et al. Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget. 2017;8:57121–33. doi:10.18632/oncotarget.19078. PMID:28915659.
   PubMedGoogle Scholar
• Quigley DA, Tahiri A, Luders T, Riis MH, Balmain A, Borresen-Dale AL, Bukholm I, Kristensen V. Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Oncoimmunology. 2017;6:e1356142. doi:10.1080/2162402X.2017.1356142. PMID:29147603.
   PubMed Web of Science ®Google Scholar
• Clancy T, Dannenfelser R, Troyanskaya O, Malmberg KJ, Hovig E, Kristensen V. Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Curr Pharm Des. 2017;23:4716–25. PMID:28699527.
   PubMed Web of Science ®Google Scholar
• Quigley DA, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol. 2015;9:2054–62. doi:10.1016/j.molonc.2015.10.003. PMID:26607741.
   PubMed Web of Science ®Google Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24:3–15. doi:10.1007/s12282-016-0698-z. PMID:27138387.
   PubMed Web of Science ®Google Scholar
• Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, et al. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci. 2017;108:81–90. doi:10.1111/cas.13114. PMID:27801993.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57–63. doi:10.1038/35040504. PMID:11081504.
   PubMed Web of Science ®Google Scholar
• Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, Surh CD. IL-7 is critical for homeostatic proliferation and survival of naive T cells. PNAS. 2001;98:8732–7. doi:10.1073/pnas.161126098. PMID:11447288.
   PubMed Web of Science ®Google Scholar
• Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64:8451–5. doi:10.1158/0008-5472.CAN-04-1987. PMID:15548717.
   PubMed Web of Science ®Google Scholar
• Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR 3rd, Castro E, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119–31. doi:10.1084/jem.20082292. PMID:19047440.
   PubMed Web of Science ®Google Scholar
• Chintalgattu V, Nair DM, Katwa LC. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol. 2003;35:277–86. doi:10.1016/S0022-2828(03)00006-3. PMID:12676542.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes & cancer. 2011;2:1097–105. doi:10.1177/1947601911423031.
   PubMedGoogle Scholar
• Collet G, Lamerant-Fayel N, Tertil M, El Hafny-Rahbi B, Stepniewski J, Guichard A, Foucault-Collet A, Klimkiewicz K, Petoud S, Matejuk A, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2014;13:165–78. doi:10.1158/1535-7163.MCT-13-0637. PMID:24170768.
   PubMed Web of Science ®Google Scholar
• Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005;92:553–61. doi:10.1038/sj.bjc.6602374. PMID:15668703.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol: Official journal of the American Society of Clinical Oncology. 2013;31:1219–30. doi:10.1200/JCO.2012.46.2762.
   PubMed Web of Science ®Google Scholar
• Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol. 2012;13:375–84. doi:10.1016/S1470-2045(12)70049-9. PMID:22377126.
   PubMed Web of Science ®Google Scholar
• Hein A, Lambrechts D, von Minckwitz G, Haberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer. 2015;137:2981–8. doi:10.1002/ijc.29656. PMID:26100253.
   PubMed Web of Science ®Google Scholar
• Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017;70:146–55. doi:10.1016/j.ejca.2016.09.024. PMID:27817944.
   PubMed Web of Science ®Google Scholar
• Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010;15:1179–91. doi:10.1634/theoncologist.2009-0155. PMID:21045188.
   PubMed Web of Science ®Google Scholar
• Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, Ducreux M, Malka D, Boige V. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification–preliminary results. Radiology. 2011;258:291–300. doi:10.1148/radiol.10091870. PMID:20980447.
   PubMed Web of Science ®Google Scholar
• Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. Journal of the American Society of Nephrology: JASN. 2010;21:1381–9. doi:10.1681/ASN.2010020167. PMID:20538785.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Yuan X, Zheng Y, Li X, Chang JY, Wang J, Wang X, Yuan Z, Wang P. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep. 2016;6:24364. doi:10.1038/srep24364. PMID:27067388.
   PubMed Web of Science ®Google Scholar
• Bear HD, Tang G, Rastogi P, Geyer CE, Jr., Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1037–48. doi:10.1016/S1470-2045(15)00041-8. PMID:26272770.
   PubMed Web of Science ®Google Scholar
• Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135–44. doi:10.1016/S1470-2045(11)70397-7. PMID:22257523.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299–309. doi:10.1056/NEJMoa1111065. PMID:22276820.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger. Annals of oncology: Official journal of the European Society for Medical Oncology. 2014;25:2363–72. doi:10.1093/annonc/mdu455. PMID:25223482.
   PubMed Web of Science ®Google Scholar
• Cattin S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Ruegg C, Fürstenberger G. Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget. 2016;7:11137–50. doi:10.18632/oncotarget.7097. PMID:26840567.
   PubMed Web of Science ®Google Scholar
• Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, et al. Brief-exposure to preoperative bevacizumab reveals a TGF-beta signature predictive of response in HER2-negative breast cancers. Int J Cancer. 2016;138:747–57. doi:10.1002/ijc.29808. PMID:26284485.
   PubMed Web of Science ®Google Scholar
• Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Moller EK, Fleischer T, Rodland E, Borgen E, Garred Ø, Olsen T, et al. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23:4662–70. doi:10.1158/1078-0432.CCR-17-0160. PMID:28487444.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA, Tayade C. IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. J Immunol (Baltimore, Md: 1950). 2015;195:2591–600. doi:10.4049/jimmunol.1501138.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7. doi:10.1038/nmeth.3337. PMID:25822800.
   PubMed Web of Science ®Google Scholar
• Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79:144–6. doi:10.1002/(SICI)1097-0215(19980417)79:2%3c144::AID-IJC8%3e3.0.CO;2-T. PMID:9583728.
   PubMed Web of Science ®Google Scholar
• Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998;34:2041–5. doi:10.1016/S0959-8049(98)00282-2. PMID:10070308.
   PubMed Web of Science ®Google Scholar
• Honorati MC, Cattini L, Facchini A. IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes. Osteoarthritis Cartilage. 2004;12:683–91. doi:10.1016/j.joca.2004.05.009. PMID:15325633.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639–44. doi:10.1038/sj.bjc.6605530. PMID:20087353.
   PubMed Web of Science ®Google Scholar
• Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, et al. Cytokine profiling of tumor 3interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology. 2016;5:e1248015. doi:10.1080/2162402X.2016.1248015. PMID:28123884.
   PubMed Web of Science ®Google Scholar
• D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992;176:1387–98. doi:10.1084/jem.176.5.1387. PMID:1357073.
   PubMed Web of Science ®Google Scholar
• Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J immunol (Baltimore, Md: 1950). 2010;185:203–10. doi:10.4049/jimmunol.0903573.
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O, Falk K. CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells. Blood. 2009;113:827–36. doi:10.1182/blood-2008-04-150524. PMID:18941119.
   PubMed Web of Science ®Google Scholar
• Massena S, Christoffersson G, Vagesjo E, Seignez C, Gustafsson K, Binet F, Herrera Hidalgo C, Giraud A, Lomei J, Weström S, et al. Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood. 2015;126:2016–26. doi:10.1182/blood-2015-03-631572. PMID:26286848.
   PubMed Web of Science ®Google Scholar
• Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G, et al. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One. 2009;4:e6119. doi:10.1371/journal.pone.0006119. PMID:19582164.
   PubMed Web of Science ®Google Scholar
• Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer. 1998;78:361–5. doi:10.1002/(SICI)1097-0215(19981029)78:3%3c361::AID-IJC17%3e3.0.CO;2-9. PMID:9766572.
   PubMed Web of Science ®Google Scholar
• Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a “fine-tuning cytokine” in inflammation processes. Arthritis Rheum. 2001;44:2176–84. doi:10.1002/1529-0131(200109)44:9%3c2176::AID-ART371%3e3.0.CO;2-4. PMID:11592383.
   PubMed Web of Science ®Google Scholar
• Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J, Demoulin JB. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 2010;38:e120. doi:10.1093/nar/gkq149. PMID:20215436.
   PubMed Web of Science ®Google Scholar
• Park J, Kim S, Joh J, Remick SC, Miller DM, Yan J, Kanaan Z, Chao JH, Krem MM, Basu SK, et al. MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget. 2016;7:43960–73. PMID:27259262.
   PubMedGoogle Scholar
• Maniati E, Hagemann T. IL-17 mediates resistance to anti-VEGF therapy. Nat Med. 2013;19:1092–4. doi:10.1038/nm.3333. PMID:24013745.
   PubMed Web of Science ®Google Scholar
• Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005;118:3759–68. doi:10.1242/jcs.02483. PMID:16105884.
   PubMed Web of Science ®Google Scholar
• Siedlecki J, Wertheimer C, Wolf A, Liegl R, Priglinger C, Priglinger S, Eibl-Lindner K. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2017;255:963–72. doi:10.1007/s00417-017-3595-z. PMID:28161830.
   PubMed Web of Science ®Google Scholar
• Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ. Evidence for NK cell subsets based on chemokine receptor expression. J immunol (Baltimore, Md: 1950). 2006;177:7833–40. doi:10.4049/jimmunol.177.11.7833.
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317:620–31. doi:10.1016/j.yexcr.2010.12.017. PMID:21376175.
   PubMed Web of Science ®Google Scholar
• Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J immunol (Baltimore, Md: 1950). 1999;163:6236–43.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68:8437–45. doi:10.1158/0008-5472.CAN-08-1440. PMID:18922917.
   PubMed Web of Science ®Google Scholar
• Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086–95. doi:10.1158/1535-7163.MCT-09-0366. PMID:19671735.
   PubMed Web of Science ®Google Scholar
• Carson WE, 3rd, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. Clinical cancer Research: An official journal of the American Association for Cancer Research. 2004;10:3401–9. doi:10.1158/1078-0432.CCR-1016-03. PMID:15161695.
   PubMed Web of Science ®Google Scholar
• Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 2001;15:156–65. doi:10.1006/cyto.2001.0935. PMID:11554785.
   PubMed Web of Science ®Google Scholar
• Jackman RW, Rhoads MG, Cornwell E, Kandarian SC. Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway. Exp Cell Res. 2009;315:3242–9. doi:10.1016/j.yexcr.2009.08.020. PMID:19732770.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285–94. doi:10.1097/00054725-199911000-00009. PMID:10579123.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J immunol (Baltimore, Md: 1950). 1998;160:5869–73.
   PubMed Web of Science ®Google Scholar
• Jin P, Zhao Y, Liu H, Chen J, Ren J, Jin J, Bedognetti D, Liu S, Wang E, Marincola F, et al. Interferon-gamma and Tumor Necrosis Factor-alpha Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Sci Rep. 2016;6:26345. doi:10.1038/srep26345. PMID:27211104.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285–94. doi:10.1097/00054725-199911000-00009. PMID:10579123.
   PubMed Web of Science ®Google Scholar
• Benjamini YaH. Y Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statistic society. 1995;57:289–300.
   Google Scholar